STAP-2 protein promotes prostate cancer growth by enhancing epidermal growth factor receptor stabilization

Received for publication, June 18, 2017, and in revised form, October 3, 2017 Published, Papers in Press, October 6, 2017, DOI 10.1074/jbc.M117.802884

Yuichi Kitaj‡1, Masashi Iwakami‡1, Kodai Saitoh‡, Sumihito Togi‡, Serina Isayama‡, Yuichi Sekine‡, Ryuta Muromoto‡, Jun-ichi Kashiwakura‡, Akihiko Yoshimura‡, Kenji Oriani‡, and Tadashi Matsuda‡2

From the ‡Department of Immunology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-Ku, Sapporo, Hokkaido 060-0812, the ‡Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo 160-8582, and the ‡Department of Hematology, International University of Health and Welfare, 4-3 Kouzunomori, Narita, Chiba 286-8686, Japan

Edited by George N. DeMartino

Signal-transducing adaptor family member-2 (STAP-2) is an adaptor protein that regulates various intracellular signaling pathways and promotes tumorigenesis in melanoma and breast cancer cells. However, the contribution of STAP-2 to the behavior of other types of cancer cells is unclear. Here, we show that STAP-2 promotes tumorigenesis of prostate cancer cells through up-regulation of EGFR receptor (EGFR) signaling. Tumor growth of a prostate cancer cell line, DU145, was strongly decreased by STAP-2 knockdown. EGFR-induced gene expression and phosphorylation of AKT, ERK, and STAT3 were significantly decreased in STAP-2 knockdown DU145 cells. Mechanistically, we found that STAP-2 interacted with EGFR and enhanced its stability by inhibiting c-CBL-mediated EGFR ubiquitination. Our results indicate that STAP-2 promotes prostate cancer progression via facilitating EGFR activation.

Intracellular signaling contributes to various cell fates, such as proliferation, differentiation, and survival/death. Aberrant activation of signaling pathways that promote cell proliferation is a cause of carcinogenesis, and it is, therefore, important to determine the mechanisms underlying this process to facilitate the development of anticancer therapies. Epidermal growth factor receptor (EGFR) is the receptor for EGF, TGFα, and HB-EGF, and its activation is required for optimal cell proliferation and development of dermis, lung, and digestive organs (1, 2). Phosphorylated tyrosine and lysine residues of EGFR are associated with JAK and PI3K, inducing ERK- and STAT-mediated gene expression and cell proliferation (2). After ligand binding, EGFR translocates from the plasma membrane to endosomes. Non-ubiquitinated EGFR then returns to the plasma membrane, but ubiquitinated EGFR is degraded in lysosomes (3, 4). EGFR ubiquitination is facilitated by c-CBL, an E3 ubiquitin ligase, which down-regulates EGFR signaling (5, 6). A gain-of-function mutation in EGFR induces aberrant cell proliferation and carcinogenesis, and gefitinib, an EGFR inhibitor, is used to treat lung cancer (2, 7). EGFR signals are mediated by several kinases, and some steps are regulated by specific adaptor proteins. It is possible that proteins relating to EGFR signals may be suitable targets for anticancer drugs.

STAP-2 was originally identified as a protein that interacts with c-Fms, which is a leukemia oncogene that regulates macrophage proliferation and differentiation (8). Our previous studies showed that STAP-2 modulates STAT3- and STAT5-mediated gene expression and promotes Fas-induced caspase-8 activation in T cells (8–10). Furthermore, FceRI, and Toll-like receptor signals are also up-regulated in macrophages and dendritic cells by STAP-2 (11, 12). These findings indicate that STAP-2 regulates immune responses and inflammation. In addition, STAP-2 associates with breast tumor kinase and STAT3, leading to proliferation of T47D breast cancer cells (13). STAP-2 also enhances breast tumor kinase-mediated STAT5 activation (14, 15). In B16F10 cells, STAP-2 positively regulates the protein levels of tyrosinase, which determines tumor invasion via controlling chemokine receptor expression (16). STAP-2 can also bind to BCR-ABL, a fusion oncoprotein of chronic myeloid leukemia, leading to significant enhancement of its downstream signals (17). Thus, STAP-2 is also involved in the development and/or progression of some types of malignancies.

In this study, we show that STAP-2 promotes tumorigenesis of prostate cancer cells in the mouse xenograft model. STAP-2 knockdown inhibited prostate cancer cell growth and decreased activation of EGFR signaling. STAP-2 interacted with EGFR and inhibited CBL-mediated EGFR ubiquitination, resulting in up-regulation of EGFR protein levels. Our results indicate that STAP-2 promotes tumorigenesis of prostate cancer cells and indicate that STAP-2 is a valid target for prostate cancer treatments.

Results

STAP-2 is highly expressed in breast cancer and prostate cancer cell lines

We previously reported that STAP-2 promotes cell proliferation and tumorigenesis of melanoma and breast cancer cells (13, 16). Here, we asked whether STAP-2 contributes to the proliferation of other types of cancer cells. To this end, we investigated
STAP-2 expression in various cancer cell lines and human tissues using qPCR (Fig. 1A). Cancer cell lines tended to express higher STAP-2 mRNA than normal cells. Especially, human prostate cancer cell lines (DU145 and LNCaP) expressed STAP-2 at high levels, similarly to breast cancer cell lines (T47D and MCF7). We therefore investigated whether STAP-2 contributes to cell proliferation of prostate cancer cells. STAP-2 shRNA-expressing DU145 cells were prepared, and the knockdown efficiency was confirmed by qPCR and immunoblotting (Fig. 1B and C). Not only cell proliferation but also survival of STAP-2–knockdown DU145 cells was significantly decreased compared with control shRNA-expressing cells (Fig. 1D and E). We then asked whether STAP-2 contributes to cell proliferation of LNCaP cells, an androgen receptor–positive human prostate cell line, by lentiviral knockdown of STAP-2. STAP-2 knockdown decreased cell growth of LNCaP cells, similar to DU145 cells (Fig. 1F and G). To investigate whether STAP-2 promotes prostate tumor growth in vivo, we injected STAP-2–knockdown DU145 cells into BALB/c nude mice and measured tumor growth. DU145 tumor growth at the sites of injection was significantly reduced by STAP-2 knockdown, and tumor-induced splenomegaly was also decreased in STAP-2–knockdown tumor-bearing mice (Fig. 1I and J). These findings suggest that STAP-2 is required for tumor formation and proliferation of prostate cancer cells.

STAP-2 up-regulates EGFR signaling

High levels of EGFR expression are associated with high risk and advanced stages of prostate cancer (18). In addition, most metastases of hormone-refractory prostate cancers express EGFR (19). Thus, EGFR is a component of a major transduction pathway for the growth of prostate cancer cells. Our previous studies showed that STAP-2 moves to the plasma membrane after EGF stimulation and that EGF-induced activity of STAT3 is enhanced by STAP-2 (8). Because prostate cancer cell lines express high levels of STAP-2 and respond to EGF stimulation, we hypothesized that STAP-2 may promote prostate cancer growth through up-regulation of EGFR signaling.

In DU145 cells, STAP-2 knockdown reduces phosphorylation of EGFR and of signaling molecules downstream of EGFR, such as STAT3, AKT, and ERK (Fig. 2A and B) although the protein amount of EGFR was slightly lower in STAP-2–knockdown cells than in control shRNA-expressing cells after EGF stimulation. We then investigated the contribution of STAP-2 to EGF-induced STAT3 and ERK activation using a
luciferase assay with STAT3-responsive (APRE) or ERK-responsive (SRE) reporter vectors. EGFR overexpression induced APRE- and SRE-mediated promoter activities, and the luciferase activities were further enhanced by STAP-2 overexpression in HEK293T cells (Fig. 2C). Although STAP-2 knockdown did not affect EGF mRNA levels, EGF-induced expression of Myc and Ccnd1 was decreased in STAP-2–knockdown DU145 cells (Fig. 2, D and E). Phosphorylation of EGFR, STAT3, AKT, and ERK by EGF was decreased in STAP-2–knockdown LNCaP cells (Fig. 2, F and G). STAP-2–knockdown LNCaP cells showed reduced expression of the EGF-responsible genes Myc and Ccnd1 after EGF stimulation (Fig. 2H). Furthermore, gefitinib, an EGFR inhibitor, significantly inhibited cell proliferation in control shRNA-expressing DU145 cells (Fig. 2I). In STAP-2 shRNA-expressing DU145 and LNCaP cells, proliferation was low and was not affected by gefitinib.

Our Western blot analysis and luciferase assays strongly indicated that STAP-2 enhances phosphorylation of EGFR and downstream signals after EGF stimulation. The involvement of STAP-2 in EGFR signaling is likely to be required for maximal cell growth of DU145 and LNCaP cells. Of note, STAP-2–knockdown DU145 cells showed similar levels of proliferation under DMSO and gefitinib treatment conditions; likewise, gefitinib inhibited DU145 cell growth only when STAP-2 existed. Therefore, STAP-2 enhances the proliferation of prostate cancer cells through up-regulation of EGFR signaling.

**STAP-2 enhances EGFR stability by inhibiting its ubiquitination**

To elucidate the mechanism of STAP-2–mediated up-regulation of EGFR signaling, we investigated the interaction between STAP-2 and EGFR by immunoprecipitation. STAP-2 was co-immunoprecipitated with EGFR (Fig. 3A). EGFR K721A is a loss-of-function EGFR mutant because of deficient dimerization and internalization (2). When EGFR K721A was expressed with STAP-2, the binding of the two proteins could not be detected (Fig. 3B). In DU145 cells, endogenous STAP-2–EGFR interaction was enhanced by EGF stimulation (Fig. 3, C and D). STAP-2 contains three functional domains: a PH domain, an SH2-like domain, and a proline-rich domain (Fig. 3E). We determined which STAP-2 region is required for STAP-2–EGFR interaction by immunoprecipitation. STAP-2–EGFR interaction was decreased by deletion of PH domain of STAP-2 (Fig. 3F), indicating the involvement of a PH domain in their binding. Of importance, EGFR overexpression increased phosphorylation of Tyr-250 in STAP-2 (Fig. 3G). STAP-2 Y250F mutant could not recover cell proliferation of STAP-2–knockdown DU145 cells (Fig. 3H), suggesting that
EGFR-mediated STAP-2 phosphorylation facilitates proliferation of DU145 cells. Furthermore, STAP-2 translocates to plasma membrane by EGF stimulation (Fig. 3 I). Thus, STAP-2 binds to functionally active EGFR, and EGFR-mediated STAP-2 phosphorylation contributes to full function of STAP-2 on proliferation of DU145 cells.

Activated EGFR is ubiquitinated by c-CBL, and ubiquitinated EGFR translocates from the plasma membrane to lysosomes, resulting in its degradation and down-regulation of EGFR signaling (3, 4). Next, we investigated whether this STAP-2–EGFR interaction contributes to EGFR stability because EGFR protein levels were slightly decreased in STAP-2–knockdown cells (Fig. 2, A and G). As shown in Fig. 4A, levels of EGFR rapidly decreased after EGF stimulation. However, EGFR levels were maintained when STAP-2 was overexpressed. In addition, levels of the EGFR K721A mutant did not decrease in DU145 cells independently of STAP-2 overexpression (Fig. 4D). STAP-2 overexpression completely inhibited c-CBL–dependent EGFR ubiquitination. Under these conditions, c-CBL protein levels were not affected by STAP-2 overexpression (data not shown). Furthermore, EGF-induced EGFR degradation was facilitated by STAP-2 knockdown, and this degradation was blocked by chloroquine treatment, an inhibitor of lysosomal protease (Fig. 4E). EGFR trafficking to lysosomes was also promoted in STAP-2–knockdown DU145 cells (Fig. 4, F and G). These results indicate that STAP-2 interacts with EGFR and enhances its stability by inhibiting c-CBL–mediated EGFR ubiquitination (6). Thus, we hypothesized that STAP-2–mediated EGFR stabilization may arise from down-regulation of EGFR ubiquitination by c-CBL. As shown in Fig. 4C, EGFR was ubiquitinated after EGF stimulation. Importantly, EGF-induced ubiquitination of EGFR was up-regulated in STAP-2–knockdown DU145 cells. EGFR ubiquitination responding to EGF stimulation was enhanced by c-CBL overexpression (Fig. 4D). STAP-2 overexpression completely inhibited c-CBL–dependent EGFR ubiquitination. Under these conditions, c-CBL protein levels were not affected by STAP-2 overexpression (data not shown). Furthermore, EGF-induced EGFR degradation was facilitated by STAP-2 knockdown, and this degradation was blocked by chloroquine treatment, an inhibitor of lysosomal protease (Fig. 4E). EGFR trafficking to lysosomes was also promoted in STAP-2–knockdown DU145 cells (Fig. 4, F and G). These results indicate that STAP-2 interacts with EGFR and enhances its stability by inhibiting c-CBL–mediated EGFR ubiquitination (Fig. 5).

Discussion

Autoactivation of EGFR is one of the driving forces of carcinogenesis, and EGFR inhibitors are used clinically for the treatment of some types of malignancy, such as lung cancer (7). However, phase II trials of gefitinib for prostate cancer treatment showed limited efficacy (22, 23). These studies suggest that prostate cancer cells have an unknown up-regulation mechanism of EGFR signaling, which is lacking in lung cancer...
cells. Thus, cancer treatments with EGFR inhibitors might be more effective by unveiling the detailed mechanism of EGFR. We here showed that STAP-2 enhances EGFR signaling via its stabilization and promotes tumor formation of prostate cancer cells, and our previous work demonstrated that STAP-2 enhances STAT3 transcriptional activity via their direct association (24). These studies indicated that STAP-2 enhances EGFR signaling with two steps, EGFR stabilization and STAT3 up-regulation. STAT3 is activated by not only EGFR but also IL-6R signaling, and blockade of IL-6R inhibits tumor growth, suggesting that STAP-2 knockdown represses prostate tumor growth by synergistic effects of down-regulation of EGFR and IL-6R signaling.

Our previous studies showed that STAP-2 associates with BRK and enhances BRK-mediated STAT3 and STAT5 activation (14, 15). BRK is known to up-regulate EGFR signaling by inhibiting c-CBL–mediated EGFR ubiquitination (25). This BRK inhibition of c-CBL results from competitive binding to EGFR at phosphorylated Tyr-1045. Taken together with the data in this study, STAP-2 function in DU145 cells is indicated to be inhibition of EGFR ubiquitination by c-CBL, resulting in restoration of EGFR on the cell surface after EGF stimulation. EGFR dimerizes after binding of its ligands and then associates with Grb2, resulting in induction of Ras activation at the plasma membrane. Activated Ras induces ERK activation and promotes cancer cell proliferation (26). Thus, the amount of surface EGFR is important for activation of Ras and ERK, and down-regulation of surface EGFR after EGF stimulation is limited by STAP-2 expression (Fig. 4B). This could be a main mechanism for STAP-2 enhancement of EGFR-dependent cell growth in DU145 cells.

EGFR forms homo- or heterodimer with HER2, HER3, or HER4 after EGF binding. These EGFR dimers activate downstream signaling, including AKT and ERK, and are regulated by c-CBL. Ubiquitination of EGFR heterodimer by c-CBL is slower than that of EGFR homodimer; therefore, HER2 and HER3 promote aberrant activation of EGFR signaling and cell proliferation in some HER2- and HER3-overexpressed cancer cells (27–29). Our data showed that STAP-2 knockdown decreased cell proliferation in DU145 cells and LNCaP cells, and STAP-2 overexpression repressed c-CBL–mediated EGFR ubiquitination, leading to restored surface expression of EGFR (Figs. 1 and 4). Moreover, STAP-2 did not associate with EGFR K721A, a dimerization-deficient mutant, indicating that STAP-2 up-regulates EGFR after its dimerization process (Fig. 3C).

STAP-2 knockdown DU145 cells showed similar levels of proliferation in DMSO and gefitinib treatment conditions; likewise, cell growth of gefitinib–treated DU145 cells was not significantly decreased by STAP-2 knockdown (Fig. 2I). Moreover, STAP-2 stabilized wild-type EGFR after EGF stimulation but not the inactive form mutant of EGFR irrespective of EGF stimulation (Fig. 4A).
These results suggest that STAP-2 knockdown represses tumor proliferation under EGFR-activating conditions but not in its inactivating conditions. Down-regulation of STAP-2 represses EGFR signaling similarly as gefitinib treatment, resulting in tumor growth inhibition, but the mechanisms of their EGFR suppression are different, suggesting that STAP-2 inhibition destabilizes not only wild-type EGFR but also gefitinib-resistant autoactive EGFR. Therefore, inhibitors of STAP-2 function have the possibility of being developed for anticancer drugs for gefitinib-resistant prostate cancers. Although our data are based on overexpression or knockdown of STAP-2, our work implies that further studies on STAP-2, including functional and structural assays, will provide new insights into cancer physiology and support the development of anticancer therapies.

**Experimental procedures**

**Reagents and cells**

Cycloheximide was purchased from WAKO. MG132 was purchased from Calbiochem. Gefinitib was purchased from Cayman Chemical. Recombinant human EGF was purchased from PeproTech. DU145 and HEK293T cells were cultured in DMEM (Sigma) supplemented with 10% FBS (Sigma) and 0.05 mM 2-mercaptoethanol (Nacalai Tesque) at 37 °C in a humidified 5% CO₂, 95% air atmosphere.

**Plasmid construction**

Construction of expression vectors of STAP-2, c-CBL, and ubiquitin was described previously (20). EGFR expression vectors were kind gifts from Dr. J. N. Ihle (St. Jude Children’s Research Hospital, Memphis, TN) and Dr. H Sakurai (Toyama University, Toyama Japan) (30).

**Knockdown**

For knockdown of STAP-2 expression in DU145 cells, shRNA-expressing vectors were constructed by inserting the oligonucleotide DNA into the AgeI/EcoRI sites of pLKO.1. Oligonucleotide DNA sequences were as follows: shControl, 5'-tctgccttgccgagaagtaacctgctttactctgccaagcaga-3'; shSTAP-2#1, 5'-ctacaatgacacgccgacctctaggtccggaattgctttgtag-3'; shSTAP-2#2, 5'-catcctgaagccaaagaagttctcgagaacacccggag-3'. shRNA-expressing lentivirus was prepared by transfecting these vectors and pVSV-G into HEK293T cells using Lipofectamine 2000 (Thermo Scientific Inc.) according to the manufacturer's instructions. DU145 cells were infected with the virus and then selected with 2.5 μg/ml puromycin for 48 h.

**qPCR**

Total RNA was isolated from DU145 cells using TRIZol (Thermo Scientific Inc.) according to the manufacturer's instructions. cDNA was synthesized from the isolated RNA.
using ReverTra Ace (TOYOBO) with random hexamer primers according to the manufacturer’s instructions. Semi-quantitative analysis of mRNA levels was performed with a MX3000P (Agilent Technologies). Primer sets for qPCR analysis were as follows: GAPDH fwd, 5’-gaatccccatcatatcctggc-3’; GAPDH rev, 5’-cataggaaggggattggtg-3’; STAP-2 fwd, 5’-ggagaagggcagaa-gttg-3’; STAP-2 rev, 5’-gaacctctgtgctccaggg-3’; Myc fwd, 5’-ccggtagttctcctcctc-3’; Myc rev, 5’-tcggattctgctcctcctc-3’; Ccnd1 fwd, 5’-gatgccactcttcacaaga-3’; Ccnd1 rev, 5’-cactctgtgctcgcagacc-3’.

**Immunoprecipitation**

DU145 cells were grown in 60-mm dishes semiconfluently and then transfected with the indicated expression vectors using Lipofectamine 2000 according to the manufacturer’s instructions. The cells were cultured in serum-free DMEM for 2 h and then stimulated with 30 or 100 ng/ml human recombinant EGF (Peprotech) for the indicated periods at 48 h post-transfection and then lysed in lysing buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% Nonidet P-40, protease inhibitor mixture (Sigma)). For the ubiquitination assay, the cells were lysed in radioimmunoprecipitation buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholic acid, 0.1% SDS, and protease inhibitor mixture). The lysate was immunoprecipitated for 2 h with anti-EGFR antibody (Ab-1, Millipore), anti-HA antibody (HA-7, Sigma), or anti-Myc antibody (9E10, Sigma) together with protein A-Sepharose beads (GE Healthcare). The protein was separated with SDS-PAGE and then blotted with the following antibodies; anti-FLAG antibody (M2, Sigma), anti-EGFR antibody (Santa Cruz Biotechnology, Inc.), anti-ubiquitin antibody (P4D1, Santa Cruz Biotechnology), anti-phosphotyrosine antibody (4G10, Millipore), anti-phospho-EGFR antibody (pY1173, Santa Cruz Biotechnology), anti-STAT3 antibody (Cell Signaling Technology), anti-phospho-STAT3 antibody (Cell Signaling Technology), anti-AKT antibody (B-1, Santa Cruz Biotechnology), anti-phospho-AKT antibody (Cell Signaling Technology), anti-ERK antibody (Cell Signaling Technology), anti-phospho-ERK antibody (Cell Signaling Technology), and anti-β-actin antibody (Sigma).

**Luciferase assay**

HEK293T cells were grown in a 24-well plate semiconfluently and then transfected with pcI-EGFR-HA, pcDNA3.1-Myc-STAP-2, pTK-RLuc, pGL3-APRE, and pGL3-SRE using Lipofectamine 2000 according to the manufacturer’s instructions. The cells were lysed at 48 h post-transfection, and then luciferase activity was determined using the Dual-Luciferase reporter assay system (Promega) with a luminometer (ATTO). pGL3-APRE and pGL3-SRE were kind gifts from Dr. H. Maita (Hokkaido University, Japan).

**Cell proliferation assay**

Cell proliferation of DU145 cells was measured using Cell Counting Kit-8 (WAKO) as described previously (16). Briefly, DU145 cells (5000 cells/well) were seeded on a 96-well plate and cultured for the indicated periods. Then 10 μl of WST solution was added to the cells. After culturing the cells for 3 h, absorbance at 450 nm was measured with a plate reader (Bio-Rad).

**In vivo tumor progression**

DU145 cells (5.0 × 10⁶ cells) were subcutaneously injected into the right flank of BALB/c nude mice (female, 4 weeks old). Tumor diameter was measured with a caliper, and the tumor volume was calculated by the formula, volume = 0.52 × (width)² × length.

**Biotinylation of plasma membrane proteins**

Control or STAP-2 shRNA–expressing DU145 cells were grown in 100-mm dishes semiconfluently and cultured in serum-free DMEM for 2 h. After EGF stimulation, the cells were washed with cold PBS and then incubated with 3 ml of HEPES, pH 8.0, 150 mM NaCl, 0.5 mg/ml Biotin-Sulfo-NHS on ice for 1 h. The cells were incubated with PBS containing 50 mM glycine for 5 min on ice and then lysed with 800 μl of lysing buffer for 10 min. Cellular debris in the lysates was disrupted by sonication and clarified by centrifugation. The supernatants were mixed with 25 μl of avidin-Sepharose (Sigma) and incubated for 2 h. The beads were washed three times with lysing buffer, and then biotinylated proteins were eluted by boiling with SDS sample buffer.

**Immunofluorescence**

HeLa cells were grown semiconfluently on 12-mm glass coverslips (Matsunami Glass) and transfected with pcDNA3.1-Myc-STAP-2 using Lipofectamine 2000. The cells were starved for 2 h at 48 h post-transfection and then stimulated with 100 ng/ml EGF for 10 min. Control or STAP-2 shRNA–expressing DU145 cells were stimulated with 100 ng/ml EGF for 20 min. The cells were fixed and stained using anti-EGFR (Ab-1, Millipore) and anti-LAMP1 antibody (Cell Signaling Technology) as described previously (31).

Author contributions—Y. K., M. I., K. S., S. T., and S. I. performed experiments; Y. S., R. M., and K. J. analyzed data; A. Y. distributed materials; Y. K. and K. O. wrote the paper; and T. M. designed experiments, supervised the project, and wrote the paper.

**References**

1. Threadgill, D. W., Dlugosz, A. A., Hansen, L. A., Tenenbaum, T., Lichti, U., Yee, D., LaManita, C., Mourtou, T., Herrup, K., and Harris, R. C. (1995) Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 269, 230–234
2. Jorissen, R. N., Walker, F., Pouliot, N., Garrett, T. P., Ward, C. W., and Burgess, A. W. (2003) Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell Res. 284, 31–53
3. Sorkin, A., and von Zastrow, M. (2009) Endocytosis and signalling: intertwining molecular networks. Nat. Rev. Mol. Cell Biol. 10, 609–622
4. Marmor, M. D., and Yarden, Y. (2004) Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene 23, 2057–2070
5. Grevdal, L. M., Stang, E., Sorkin, A., and Madshus, I. H. (2004) Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp. Cell Res. 300, 388–395
6. Levkovitz, G., Waterman, H., Zamir, E., Kam, Z., Oved, S., Langdon, W. Y., Beguinot, L., Geiger, B., and Yarden, Y. (1998) c-Cbl/Sli-1 regulates

19398 J. Biol. Chem. (2017) 292(47) 19392–19399
endocytic sorting and ubiquitination of the epidermal growth factor receptor. *Genes Dev.* **12**, 3663–3674

7. Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., Fujita, Y., Okinaga, S., Hirano, H., Yoshimori, K., Harada, T., et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N. Engl. J. Med.* **362**, 2380–2388

8. Minoguchi, M., Minoguchi, S., Aki, D., Joo, A., Yamamoto, T., Yumioka, T., Matsuda, T., and Yoshimura, A. (2003) STAP-2/BKS, an adaptor/docking protein, modulates STAT3 activation in acute-phase response through its YXXQ motif. *J. Biol. Chem.* **278**, 11182–11189

9. Sekine, Y., Yamamoto, C., Kakisaka, M., Muromoto, R., Kon, S., Ashitomi, D., Fujita, N., Yoshimura, A., Oritani, K., and Matsuda, T. (2014) Signal-transducing adaptor protein-2 regulates Fas-mediated T cell apoptosis by interacting with caspase-8. *J. Immunol.* **188**, 6194–6204

10. Sekine, Y., Yamamoto, T., Yumioka, T., Sugiyama, K., Tsuji, S., Oritani, K., Shimoda, K., Minoguchi, M., Yoshimura, A., and Matsuda, T. (2005) Physical and functional interactions between STAP-2/BKS and STAT5. *J. Biol. Chem.* **280**, 8188–8196

11. Sekine, Y., Nishida, K., Yamasaki, S., Muromoto, R., Kon, S., Ashitomi, J., Saitoh, K., Togi, S., Yoshimura, A., Oritani, K., and Matsuda, T. (2014) Signal-transducing adaptor protein-2 controls the IgE-mediated, mast cell-mediated anaphylactic responses. *J. Immunol.* **192**, 3488–3495

12. Sekine, Y., Yumioka, T., Yamamoto, T., Muromoto, R., Imoto, S., Sugiyama, K., Oritani, K., Shimoda, K., Minoguchi, M., Akira, S., Yoshimura, A., and Matsuda, T. (2006) Modulation of TLR4 signaling by a novel adaptor protein signal-transducing adaptor protein-2 in macrophages. *J. Immunol.* **176**, 380–389

13. Ikeda, O., Sekine, Y., Mizushima, A., Nakasui, M., Miyasaka, Y., Yamamoto, C., Muromoto, R., Nanbo, A., Oritani, K., Yoshimura, A., and Matsuda, T. (2010) Interactions of STAP-2 with Bkr and STAT3 participate in cell growth of human breast cancer cells. *J. Biol. Chem.* **285**, 38093–38103

14. Ikeda, O., Miyasaka, Y., Sekine, Y., Mizushima, A., Muromoto, R., Nanbo, A., Yoshimura, A., and Matsuda, T. (2009) STAP-2 is phosphorylated at tyrosine-250 by Brk and modulates Bkr-mediated STAT3 activation. *Biochem. Biophys. Res. Commun.* **384**, 71–75

15. Ikeda, O., Mizushima, A., Sekine, Y., Yamamoto, C., Muromoto, R., Nanbo, A., Oritani, K., Yoshimura, A., and Matsuda, T. (2011) Involvement of STAP-2 in Bkr-mediated phosphorylation and activation of STAT5 in breast cancer cells. *Cancer Sci.* **102**, 756–761

16. Sekine, Y., Togi, S., Muromoto, R., Kon, S., Kitai, Y., Yoshimura, A., Oritani, K., and Matsuda, T. (2015) STAP-2 protein expression in B16F10 melanoma cells positively regulates protein levels of tyrosinase, which determines organs to infiltrate in the body. *J. Biol. Chem.* **290**, 17462–17473

17. Sekine, Y., Ikeda, O., Mizushima, A., Ueno, Y., Muromoto, R., Yoshimura, A., Kanakura, Y., Oritani, K., and Matsuda, T. (2012) STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis. *Oncogene* **31**, 4384–4396

18. van Bohlen, A., Varella-Garcia, M., Korch, C., Johannes, W. U., Smith, E. E., Miller, H. L., Nordeen, S. K., Miller, G. J., and Lucia, M. S. (2003) Molecular characterization of human prostate carcinoma cell lines. *Prostate* **57**, 205–225

19. Gan, Y., Shi, C., Inge, L., Hihner, M., Balducci, L., and Huang, Y. (2010) Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. *Oncogene* **29**, 4947–4958

20. Sekine, Y., Yamamoto, C., Ikeda, O., Muromoto, R., Nanbo, A., Oritani, K., Yoshimura, A., and Matsuda, T. (2009) The protein content of an adaptor protein, STAP-2 is controlled by E3 ubiquitin ligase Cbl. *Biochem. Biophys. Res. Commun.* **384**, 187–192

21. Sekine, Y., Tsuji, S., Ikeda, O., Sugiyama, K., Oritani, K., Shimoda, K., Muromoto, R., Ohbayashi, N., Yoshimura, A., and Matsuda, T. (2007) Signal-transducing adaptor protein-2 regulates integrin-mediated T cell adhesion through protein degradation of focal adhesion kinase. *J. Immunol.* **179**, 2397–2407

22. Canil, C. M., Moore, M. J., Winquist, E., Baetz, T., Pollak, M., Chi, K. N., Berry, S., Ernst, D. S., Douglas, L., Brundage, M., Fisher, B., McKenna, A., and Seymour, L. (2005) Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. *J. Clin. Oncol.* **23**, 455–460

23. Small, E. J., Fontana, J., Tannir, N., DiPaola, R. S., Wilding, G., Rubin, M., Iacona, R. B., and Kabbinavar, F. F. (2007) A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. *BJU Int.* **100**, 765–769

24. Matsuda, T., Muromoto, R., Sekine, Y., Togi, S., Kitai, Y., Kon, S., and Oritani, K. (2015) Signal transducer and activator of transcription 3 regulation by novel binding partners. *World J. Biol. Chem.* **6**, 324–332

25. Li, X., Lu, Y., Liang, K., Hsu, J. M., Albarracin, C., Mills, G. B., Hung, M. C., and Fan, Z. (2012) Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR. *Oncofase* **31**, 4372–4383

26. Hanafusa, H., Torii, S., Yasunaga, T., and Nishida, E. (2002) Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. *Nat. Cell Biol.* **4**, 850–858

27. Muthuswamy, S. K., Gilman, M., and Brugge, J. S. (1999) Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. *Mol. Cell. Biol.* **19**, 6845–6857

28. Mellinghoff, I. K., Tran, C., and Sawyer, C. L. (2002) Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. *Cancer Res.* **62**, 2524–2529

29. Carrión-Salip, D., Panosa, C., Menendez, J. A., Puig, T., Oliveras, G., Pan- diella, A., De Llorens, R., and Massaguer, A. (2012) Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. *Int. J. Oncol.* **41**, 1218–1318

30. Nishimura, M., Shin, M. S., Singhirunnusorn, P., Suzuki, S., Kawanishi, M., Koizumi, K., and Sakurai, H. (2009) TAK1-mediated serine/threonine phosphorylation of epidermal growth factor receptor via p38/extracellular signal-regulated kinase: NF-κB-independent survival pathways in tumor necrosis factor α signaling. *Mol. Cell. Biol.* **29**, 5529–5539

31. Kitai, Y., Takeuchi, O., Kawakami, T., Ori, D., Suyoshi, T., Murase, M., Akira, S., and Kawai, T. (2015) Negative regulation of melanoma differentiation-associated gene 5 (MDA5)-dependent antiviral innate immune responses by Arf-like protein 5B. *J. Biol. Chem.* **290**, 1269–1280

**STAP-2 up-regulates EGFR signaling**